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Cardiovascular diseases (CVD) are the leading cause of death worldwide. CVD comprise
a range of diseases affecting the functionality of the heart and blood vessels, including
acute myocardial infarction (AMI) and pulmonary hypertension (PH). Despite their different
causative mechanisms, both AMI and PH involve narrowed or blocked blood vessels,
hypoxia, and tissue infarction. The endothelium plays a pivotal role in the development of
CVD. Disruption of the normal homeostasis of endothelia, alterations in the blood vessel
structure, and abnormal functionality are essential factors in the onset and progression
of both AMI and PH. An emerging theory proposes that pathological blood vessel
responses and endothelial dysfunction develop as a result of an abnormal endothelial
metabolism. It has been suggested that, in CVD, endothelial cell metabolism switches
to higher glycolysis, rather than oxidative phosphorylation, as the main source of ATP, a
process designated as the Warburg effect. The evidence of these alterations suggests
that understanding endothelial metabolism and mitochondrial function may be central
to unveiling fundamental mechanisms underlying cardiovascular pathogenesis and to
identifying novel critical metabolic biomarkers and therapeutic targets. Here, we review
the role of the endothelium in the regulation of vascular homeostasis and we detail key
aspects of endothelial cell metabolism. We also describe recent findings concerning
metabolic endothelial cell alterations in acute myocardial infarction and pulmonary
hypertension, their relationship with disease pathogenesis and we discuss the future
potential of pharmacological modulation of cellular metabolism in the treatment of
cardiopulmonary vascular dysfunction. Although targeting endothelial cell metabolism
is still in its infancy, it is a promising strategy to restore normal endothelial functions and
thus forestall or revert the development of CVD in personalized multi-hit interventions at
the metabolic level.
Keywords: acute myocardial infarction, pulmonary hypertension, endothelial dysfunction, cellular metabolism,
glycolysis, metabolic targets, systems biology
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IMPORTANCE OF CARDIOPULMONARY
DISEASES
Cardiovascular diseases (CVD) are leading cause of death in
the world. In 2015, The World Health Organization (WHO)
estimated that 17.7 million people died from CVD, representing
31% of all global deaths (Townsend et al., 2015). Death from
CVD is associated with increasing age, with 1.4 million deaths
in individuals under 75 and 700,000 in individuals under 65
(Townsend et al., 2016).
CVD encompass a range of diseases affecting the functions
of the heart and blood vessels, driven by diverse underlying
mechanisms. In this review, we will focus on acute myocardial
infarction (AMI), a type of coronary artery disease, and
pulmonary arterial (PAH), and chronic thromboembolic
pulmonary hypertension (CTEPH). Both types of CVD share
a diseased endothelium conducive to atherosclerosis and
endothelial hyperproliferation, respectively, with consequent
narrowing of arteries, compromised blood flow and reduced
oxygen and nutrient supply to the vascular cells, eventually
leading to cardiac hypertrophy and myocardial infarction.
Atherosclerosis
Atherosclerosis, or the formation of atherosclerotic plaques,
underlies one of the major causes of morbidity and mortality
in developed and developing nations (Townsend et al., 2015).
The World Health Organization attributes an estimated 16.7
million deaths to atherosclerotic cardiovascular disease (Leopold
and Loscalzo, 2005; Hyder et al., 2007). Atherosclerotic plaque
formation and rupture is one of most common pathogenic
mechanisms of coronary artery disease, stroke, and peripheral
artery disease (Grootaert et al., 2015). Atherogenesis is the
result of complex sequences of events associated with processes
such as endothelial dysfunction, neovascularization, vascular
proliferation, apoptosis, matrix degradation, inflammation,
oxidative stress, and thrombosis (Hansson, 2005). All these
processes affect the inner lining of the artery. Eventually, arteries
become thicker by virtue of an accumulation of calcium, fat
deposits and inflammatory cells, leading to the formation of
the atherosclerotic plaque (Liu et al., 2015). Although the
pathophysiological mechanisms of atherosclerosis are yet to
be fully unveiled, increasing evidences point to a critical role
played by endothelial and metabolic dysregulation involving
downregulation of oxidative phosphorylation and fatty acid
metabolism. A complete understanding of endothelial metabolic
reprogramming underlying atherosclerosis requires further
investigation and could open new avenues in the prevention and
treatment of this disease (Moreno-Viedma et al., 2016).
Current Therapies in Atherosclerosis and AMI
The four major risk factors for developing atherosclerosis
are hypercholesterolemia, diabetes, hypertension, and cigarette
smoking (Bergheanu et al., 2017). Recent studies have shown
that an adequate control of lipoprotein levels reduces the
risk of atherosclerosis events. As such, a modification in
daily diet, an increase in physical activity and cessation
of smoking constitute the cornerstones of any intervention
aimed at the prevention and/or treatment of atherosclerosis.
While the role of the other parameters is still not clear, TG
(triglycerides), LDL-C (low density lipoprotein cholesterol), and
HDL-C (high density lipoprotein cholesterol) remain very strong
predictors of premature atherosclerosis (Catapano et al., 2016).
Hypercholesterolemia alters vascular permeability, allowing the
leaking of LDL cholesterol and deposition on the arterial
walls. There, LDL is subject to modifications that include
oxidation, enzymatic processing, and aggregation, that render the
lipoprotein particles proinflammatory and induce an immune
response. As part of this response, monocytes are recruited
to the sub-endothelial space where they differentiate into
macrophages. Macrophages may also derive from pluripotent
cells associated with blood vessels. Regardless of their origin,
macrophages in atherosclerotic lesions actively participate in
lipoprotein ingestion and accumulation giving rise to foam
cells filled with cholesterol-rich lipid droplets. These processes
lead to vascular modifications visible as fatty streaks, intimal
thickening and ruptured plaques, causing acute coronary
disease (Bergheanu et al., 2017). Vulnerable plaques contain
monocytes, macrophages and T cells, which accounts for their
instability.
The critical role played by LDL-C in atherosclerosis has
prompted the development of rational strategies to counter
the pathogenic effects of hypercholesterolemia. The use of
statins (inhibitors of HMG-CoA reductase, the rate-controlling
enzyme of the mevalonate, and cholesterol synthesis pathways)
as a pharmacological approach to lower cholesterol levels is
one of the most widely used therapies in the treatment of
atherosclerosis and acute coronary syndromes, as these drugs
show consistent clinical event reductions with a very good
safety profile (Adams et al., 2014). Other clinical studies reveal
that the use of ezetimibe (an inhibitor of intestinal cholesterol
absorption) considerably reduces LDL-C blood levels when
combined with statins (Catapano et al., 2016). An alternative
approach is the administration of fibrates, a particular class
of agonists of the peroxisome proliferator-activated receptor
α (PPAR-α) a regulator of lipoprotein metabolism, showing
a good effect in lowering TG levels as mono-therapy, even
though the results are not as promising as for the statins
(Adams et al., 2014). Recently, a largemulti-scale andmultiethnic
study was undertaken to better understand the role of genetic
and environmental factors in CVD and to identify genetic
variants associated to blood lipids levels (Klarin et al., 2018).
By using a genome wide association study (GWAS) on Million
Veterans Program (MVP), this work depicted some novel
lipid associated coding variants with CVD risk or incidence.
Individuals with mutations in ANGPTL4 (Angiopoietin-like4)
presented a lower risk to develop diabetes mellitus (type2),
those with a loss of function in PCSK9 (Proprotein convertase
subtilisin/kexin type 9) showed a reduced risk of abdominal
aortic aneurysm, and those treated with inhibitors of PDE3B
(Phosphodiesterase 3B), presented reduced levels of triglycerides
in blood (Cohen et al., 2006; Willer et al., 2013; Ahmad et al.,
2016; Dewey et al., 2017; Graham et al., 2017). These data
highlight the complexity in humans to control blood lipid
composition and the potential of a genetic approach to develop
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novel therapeutic agents for the prevention of cardiovascular
disease.
When the combination of healthier diet, lifestyle and
pharmacological treatments fail to improve the pathological
and clinical conditions in atherosclerotic patients with an
associated coronary disease, surgical intervention is considered
the best option. Coronary artery thrombosis with complete
occlusion typically leads to ST-segment elevation myocardial
infarction (STEMI). Partial occlusion, or occlusion in the
presence of collateral circulation, results in non-STEMI or
unstable angina, an acute coronary syndrome without ST-
segment elevation. Once a definitive or likely diagnosis of an
acute coronary syndrome without ST-segment elevation has
been made, the patient is triaged to either an invasive strategy
or an ischemia-guided strategy. An invasive strategy leads to
improved outcomes and is favored for the majority of patients
(Anderson and Morrow, 2017).
In patients presenting with an unstable condition or with
STEMI, urgent Percutaneous Coronary Intervention (PCI) is
performed. An ischemia-guided strategy is chosen for patients at
low risk of recurrent ischemia, especially for women. Although
PCI is currently the intervention of choice for most of these
patients, individual coronary anatomy and clinical features may
dictate the use of a different approach, such as coronary artery
bypass grafting (CABG), a surgery that reinstates cardiac blood
flow (Parsa et al., 2011). In some cases, current guidelines
also recommend an antiplatelet therapy combined with non-
vitamin K antagonist oral anticoagulant (NOACs) therapy
(Husted et al., 2014; Steffel et al., 2018). Indeed, the rates
of major complications of acute myocardial infarction have
declined dramatically with early reperfusion (PCI) associated
with antiplatelet therapy (French et al., 2010). Nevertheless,
complications are still a leading cause of death and deserve
careful consideration. Several new therapeutic approaches, such
as reducing inflammation, mitigating reperfusion injury or
inducing myocardial regeneration, are under active investigation
although, except for angiotensin converting enzyme (ACE)
inhibition, have so far not proved beneficial in the acute
care setting. Acute myocardial infarction continues to have a
major impact on global health and its management remains
a crucial challenge for scientific advancement in medicine
(Bhatt et al., 2013).
Pulmonary Hypertension
Pulmonary hypertension (PH) is a hemodynamic disease state
involving multiple clinical conditions including pulmonary
arterial hypertension (PAH) and chronic thromboembolic
pulmonary hypertension (CTEPH) (Galiè et al., 2016). They
are defined by hemodynamic parameters characterized by a
mean pulmonary artery pressure ≥ 25 mmHg at rest, measured
during right heart catheterization (Galiè et al., 2016). The
pathophysiological consequence is a gradual obstruction of
the arterial lumen leading to the development of increased
resistance of the pulmonary vasculature and, ultimately, right
ventricular failure (Galiè et al., 2009; Lang, 2015). PAH is
characterized by disease-specific lesions mainly involving the
smaller pulmonary arteries (<500µm in diameter). These
lesions feature thickening of both the external and medial
layers and changes in the endothelial monolayer accompanied
by an inflammatory infiltration and formation of complex
thrombotic lesions (Galiè et al., 2009). Unlike PAH, where
obstruction caused by remodeling likely occurs in the more
distal pulmonary arteries, CTEPH is largely associated with
prominent obstructions in the main pulmonary arteries caused
by unresolved thrombi affecting the medial and intimal layers
of the arteries (Humbert, 2010; Lang, 2015). Subsequently,
distal pulmonary arteriopathy and microvascular disease can
be triggered, indistinguishable from classic PAH (Lang and
Madani, 2014; Lang, 2015). PAH and CTEPH are both rare
and progressive vascular diseases with poor prognosis if early
diagnosis is not performed. Diagnosis is complicated by the
lack of biomarkers and patient-specific symptoms (Humbert
et al., 2014). Whereas, PAH has an estimated prevalence of
15 to 50 per million population (Humbert et al., 2014), the
prevalence of CTEPH is not easy to estimate, due to a long
asymptomatic period between the initiating event (pulmonary
embolism; PE) and the overt symptomatic disease. With this
caution, the prevalence of CTEPH is estimated at between 0.1 and
9.1% after diagnosis of PE (Humbert, 2010; Lang and Madani,
2014). Current therapies for PAH mainly focus on targeting
endothelial dysfunction, whereas pulmonary endarterectomy
(PEA) is the treatment of choice for CTEPH, with a possible
curative outcome (Nogueira-Ferreira et al., 2014; Jenkins, 2015).
To date, additional research is needed to learn more about
the onset and development of PH. This review will touch the
recent findings concerning the endothelium dysfunction and
metabolic alterations in PAH and CTEPH, its likely relationship
with the disease pathogenesis, and whether pharmacological
modifications on cellular metabolism might be a potential future
treatment for PH.
Current Therapies in PH
PAH is the most studied condition of all PH clinical groups.
Three key vasomotor pathways are the targets of the main
approved PAH therapies: (1) prostacyclin, (2) endothelin-1,
and (3) nitric oxide-cyclic guanosine monophosphate (cGMP).
Interventions on all three pathways aim at restoring the
imbalance of endothelial vasodilator and vasoconstrictors
mediators. However, because they have little impact on vascular
remodeling and coagulation homeostasis, they are not curative
for PAH (Humbert et al., 2014).
No targeted therapy is currently available for CTEPH
patients and, as mentioned above, pulmonary endarterectomy
(PEA) is the treatment of choice in operable patients. Features
for determining patient operability are the accessibility of
the thromboembolic material and patient comorbidities
influencing the peri- and post-operative risk. Effective PEA
results in improvement of clinical symptoms, normalization
of hemodynamics, and increased survival (Jenkins, 2015).
For patients who suffer from inoperable CTEPH or
persistent/recurrent CTEPH, Riociguat was recently approved
as the only pharmaceutical targeted treatment of CTEPH based
on the findings from the CHEST study (Hoeper, 2015) and the
PATENT-1 study (Galiè and Ghofrani, 2013). Riociguat is a
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member of the family of soluble guanylate cyclase stimulators
(sGC). It has a two-faceted mode of action, on the one hand by
increasing the sensitivity of sGC to endogenous NO, and on the
other hand by stimulating sGC activity independently of NO,
resulting in restoration of the NO-sGC-cGMP (cyclic guanosine
monophosphate) pathway, accompanied with vasodilation
and anti-fibrotic, anti-proliferative and anti-inflammatory
effects (Hoeper, 2015). The drug significantly improves the
patients’ exercise capacity and pulmonary vascular resistance
and possibly constitutes a first targeted therapy for CTEPH
(Ghofrani et al., 2013).
The limited benefits of existing therapies for PAH and
the high risk associated with PEA for CTEPH patients have
fostered recent studies that explore new therapeutic avenues.
An emerging topic suggests the occurrence of potentially
actionable metabolic abnormalities in pulmonary hypertension.
We will now focus on recent observations on the role of
EC dysfunction and metabolism in the pathophysiology of
PAH and CTEPH and the therapeutic opportunities they may
provide.
ENDOTHELIAL CELLULAR ENERGY
METABOLISM
The endothelium is a dynamic organ consisting of a single
layer of endothelial cells (ECs) lining the entire vascular system.
Independently of their anatomic location (artery, arteriole,
capillary, venule, vein) all endothelial share the common
function of maintenance of vessel homeostasis (Pober et al.,
2009; Sandoo et al., 2010). The control of vessel functions
involves regulation of the blood flow, vascular tone, physical
barrier, blood coagulation, and the inflammatory response. A
balanced production of various hormones, neurotransmitters,
and vasoactive factors is crucial for maintaining a homeostatic
vessel function (Sandoo et al., 2010). An important vasoactive
factor is eNOS-derived nitric oxide (NO), that promotes
vasodilatation and inhibits important events that contribute
to the development of vascular remodeling diseases, such
as platelet aggregation, adhesion of leukocytes, and oxidative
stress (Förstermann and Sessa, 2012). NO produced by the
endothelium also plays an important role in mitochondrial
respiration to maintain the oxygen gradient in oxygen limiting
situations (Dromparis and Michelakis, 2013). When the NO
precursor arginine and the eNOS cofactor tetrahydrobiopterin
(BH4) are not available, eNOS fails to produce NO and may
promote the formation of reactive oxygen species (ROS), causing
endothelial dysfunction and leading to atherosclerosis and PH
pathogenesis (Förstermann and Sessa, 2012).
The importance ofmaintaining physiological and homeostatic
EC functions is underlined by the development of major diseases
like cardiovascular disease, diabetes, and cancer, consequent to
endothelial dysfunction (Goveia et al., 2014). The endothelium
can be disrupted by EC damage or apoptosis which leads to a
re-endothelialization response and in some cases to the selection
of ECs with an altered phenotype (Pober et al., 2009; Nogueira-
Ferreira et al., 2014). Environmental stresses, such as oxidative
stress and metabolic disturbances, are important sources of
endothelial dysfunction, injury, and death (Pober et al., 2009).
Glycolysis
When exposed to hypoxic conditions, mitochondrial alterations
or growth factors, ECs can rapidly shift from a quiescent cellular
mode to an angiogenic state accompanied with changes in
their cell metabolism. Under basal conditions, ECs rely mostly
(>80%) on glycolysis for generating their cellular energy and
thus leaving the circulating oxygen available for underlying
oxygen-requiring tissues (De Bock et al., 2013b; Dromparis
and Michelakis, 2013; Goveia et al., 2014). In pathological
conditions with sustained suppressed oxidative phosphorylation
(OXPHOS), glycolytic flux is increased regardless of the oxygen
supply as long as glucose is available (Warburg effect) promoting
the development of highly proliferative vascular disorders
(Parra-bonilla et al., 2010; Dromparis and Michelakis, 2013).
This predominantly reliance on glycolysis over the use of
more efficient mitochondrial oxidation is supported by the
presence of fewer mitochondria when compared to cell types
relying on mitochondrial respiration. Regardless the presence
of sufficient oxygen to maintain mitochondrial respiration,
glycolytic flux quickly converts pyruvate to lactate, followed by an
increase in glucose uptake (Parra-bonilla et al., 2010). Sustained
upregulation of glycolysis and suppression of OXPHOS is often
accompanied with a normoxic activation of HIF1α, leading
to activation/upregulation of several glycolytic enzymes and
further suppressing mitochondrial respiration (Dromparis and
Michelakis, 2013).
The glycolytic enzyme phosphofructokinase-2/fructose-2,6-
biphosphatase 3 (PFKFB3) is important for maintaining
glycolysis and it has been shown that PFKFB3 inactivation
reduces EC proliferation (De Bock et al., 2013b). PFKFB3
catalyzes the synthesis of fructose-2,6-biphosphate (Fru-2,6-
P2), an allosteric activator of phosphofructokinase 1 (PFK-1)
and a potent stimulator of glycolysis. Partial reduction of the
glycolytic flux by PFKFB3 inhibition was shown to be sufficient
to impair EC proliferation without induction of cell death
as caused by 2DG (2-deoxy-D-glucose) (Schoors et al., 2014).
Another important glycolytic enzyme is the mitochondrial “gate-
keeper” enzyme pyruvate dehydrogenase (PDH) that acts as a
promoter of the entry of pyruvate in mitochondria (Cottrill
and Chan, 2013). PDH can be phosphorylated and inhibited
through the activity of pyruvate dehydrogenase kinases (PDKs),
resulting in a reduced mitochondrial contribution to energy
production and concomitant promotion of aerobic glycolysis
(Ryan and Archer, 2015).
PDKs are induced by HIF1α and PDHs are additionally
inhibited by altered mitochondrial Ca2+ signaling (Dromparis
and Michelakis, 2013). Upon PDH inhibition, pyruvate,
rather than entering the mitochondrial respiratory chain, is
converted to lactate by the enzyme lactate dehydrogenase (LDH)
allowing the transformation of NADH to NAD+, which is
crucial for maintaining further glycolysis. Lactate is released
to the extracellular microenvironment via monocarboxylate
transporter 4 (MCT4). It can also enter the cells through
monocarboxylate transporter 1 (MCT1) and used to feed
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the TCA cycle under low oxygen conditions, promoting the
so-called “reverse Warburg effect,” a process that illustrates the
symbiotic relationship between lactate-producing and lactate-
consuming normal and pathological cells (Semenza, 2008), an
important adaptive mechanism to continuously changing micro-
environmental conditions (Semenza, 2008; Draoui and Feron,
2011). Moreover, the increase in lactate production generates
an extracellular acidification of the microenvironment which
promotes the activity of certain metalloproteases that disrupt
the extracellular matrix, which also leads to an infiltration of
the vascular wall with inflammatory cells and other cell types
(Bonuccelli et al., 2010).
Glycolysis is also connected to the pentose phosphate pathway
(PPP), a metabolic pathway that generates NADPH and ribose-5-
phosphate, essential for the biosynthesis of lipids and nucleotides.
PPP plays a pivotal role in the production of NADPH moieties
which provide the reducing equivalents necessary for the
synthesis of fatty acids and for the scavenging of ROS to promote
cell survival (Patra and Hay, 2014). The altered metabolic profile
of mitochondrial suppression along with increased glycolytic
rates causing a dysfunctional vasculature is similar to that of other
rapidly proliferating healthy and malignant cell types, in which a
shift occurs from mitochondrial respiration to lactate-producing
aerobic glycolysis in order to sustain their rapid growth and to
block apoptosis (Vander Heiden et al., 2009; Parra-bonilla et al.,
2010; De Bock et al., 2013a).
Mitochondrial Respiration
Mitochondria are considered the quintessential cellular engine
since its primary function is energy production in the form
of adenosine triphosphate (ATP). ATP is essential to sustain
cellular bioenergetic demands, glucose being the principal carbon
substrate needed to generate ATP. OXPHOS is the mitochondrial
metabolic pathway that enables cells to synthesize ATP from
oxidation of nutrients. For each glucose molecule that enters
the glycolytic pathway, 2 pyruvate molecules are produced with
a net energy of 2 ATP molecules. Subsequent pyruvate uptake
into mitochondria results in 36 ATP molecules with minimal
production of lactate under physiological conditions (Vander
Heiden et al., 2009; Parra-bonilla et al., 2010). This process
is oxygen-dependent and, considering its high efficiency, it is
the predominant source of energy in mammalian cells(Parra-
bonilla et al., 2010). Individual cell growth is controlled by
environmental nutrient availability; therefore, cells only take up
nutrients for cell division when stimulated by growth factors
to avoid abnormal proliferation. In addition to ATP, active
cell division requires nucleotides, amino acids, and lipids. To
maintain cell growth and concomitant increase in biomass,
part of the glucose must be redirected to the generation of
critical macromolecular precursors such as acetyl-CoA, glycolytic
intermediates, and ribose for the biosynthesis of, respectively,
fatty acids, non-essential amino acids, and nucleotides (Vander
Heiden et al., 2009). In order to promote this flow of carbon
substrates toward biomass accumulation, rapidly growing cells
are endowed with mechanisms that favor glycolysis over
mitochondrial oxidation.
Although the major function of mitochondria is ATP
production, these organelles are also important regulators of cell
survival, ion homeostasis (H+, Ca2+) and cellular redox status
(Collins et al., 2012). Tight regulation of the mitochondrial ion
status is of great importance in tissues with limited oxygen
consumption, like the vasculature and the lung, which facilitate
the diffusion of oxygen to more oxygen-requiring tissues.
Disturbances in mitochondrial ion status have direct and indirect
consequences on cell function, growth, and survival (Dromparis
and Michelakis, 2013). Altered mitochondrial morphology and
function prompted by factors such as NO status have been
associated with vascular endothelial dysfunction and to diverse
pathological conditions, including cardiovascular disorders,
muscular degeneration, and cancer (Collins et al., 2012;
Dromparis and Michelakis, 2013). Mitochondrial metabolism
contributes actively to the production of reactive oxygen species
(ROS). Mitochondria regulate redox signaling to and from
mitochondria and initiate cellular apoptosis (Rizzuto et al.,
2012). Oxidative stress is considered a major contributor to the
destruction of well-balanced homeostatic mechanisms, causing
cell injury either through direct oxidation of cellular proteins,
lipids, and DNA or via cell death signaling pathways (Leopold
and Loscalzo, 2005; Sinha et al., 2014).
The sensitivity of cells to glycolytic and OXPHOS inhibitors
(such as2DG, and Oligomycin, respectively) can be used to
help unveil the cell dependency on a specific energy-generating
pathway (Suganuma et al., 2010). Such studies have shown that,
in spite of the importance of the glycolytic pathway, especially
under hypoxic conditions, the majority of cells use a combination
of OXPHOS and glycolysis as a strategy for energy production,
pointing out the importance of metabolic plasticity for cell
survival under shifting environments and the complexity of
metabolic adaptations in disease (Moreno-Sánchez et al., 2007).
ROS-Oxidative Stress
During OXPHOS, electrons from NADH and FADH2 molecules
(electron donors) are transferred to electron acceptors, such
as oxygen. These redox reactions are carried out by protein
complexes located in the mitochondrial inner membrane,
and release energy which is used to form ATP (Vega-
Naredo et al., 2014). Small amounts of these electrons
form prematurely mitochondria-derived reactive oxygen species
(mROS), such as superoxide (O−2 ). ROS are oxygen-containing
chemically reactive species which play important signaling
roles to sustain fundamental cellular functions under various
physiological conditions (Förstermann, 2008). High levels of
oxygen and increased mitochondrial activity leads to excessive
ROS production overcoming the buffer capacity of usable
antioxidant systems results in oxidative stress causing increased
cell death and endothelial dysfunction (Leopold and Loscalzo,
2005; Pangare and Makino, 2012; Dromparis and Michelakis,
2013; Li et al., 2014). Mitochondria-based manganese superoxide
dismutase (MnSOD, or SOD2) has an immediately anti-oxidative
effect through the conversion of superoxide to the more stable
and diffusible H2O2. After leaving mitochondria, physiological
levels of hydrogen peroxide (H2O2) function as an important
signaling system, acting on several redox sensitive targets in the
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cytoplasm (HIF1α) and the cell membrane (K+ channels) and
also with some proliferation-related enzymes (Fukai and Ushio-
Fukai, 2011; Dromparis and Michelakis, 2013). Several other
enzyme systems can produce ROS in the vascular wall, notably
NADPH oxidase, xanthine oxidase, and eNOS, a dysfunctional
endothelial NO synthase in which oxygen reduction is uncoupled
from NO synthesis (Brandes and Kreuzer, 2005; Förstermann,
2008; Li et al., 2014; Xia et al., 2017). These oxidases are
multisubunit enzyme complexes that produce superoxide from
molecular oxygen and NADPH as electron donor (Drummond
et al., 2011).
Imbalances in the cellular oxidative status play significant
roles in the pathophysiology of vascular diseases (Santos et al.,
2011). Some cells might resort to a metabolic switch to glycolysis
as a mechanism to reduce production of ROS and thus to protect
themselves from mitochondrial-mediated apoptosis (Ryan and
Archer, 2015). The crucial role of oxidative stress in CVDs
makes it an attractive target for therapy. However, recent studies
in patients with cardiovascular symptoms showed that the use
of supplementary antioxidants such as vitamins E and C had
little therapeutic effect. This was mainly due to the limited
specificity for ROS producing factors and to the requirement
of high antioxidant doses which could worsen vascular function
(Münzel et al., 2010, 2017). Whilst, novel therapeutic strategies
propose to target more precise ROS producing sites such as the
mitochondria, it is not an easy task as those are important dose-
dependent signaling molecules which could have a detrimental
effect on key body functions. Therefore, more detailed studies
are needed to elucidate the potential therapeutic effects of
antioxidant treatments(Münzel et al., 2017).
THE IMPORTANCE OF THE
ENDOTHELIUM IN DISEASE
Endothelial Dysfunction in Acute
Myocardial Infarction
Acute myocardial infarction (AMI) is the development of
myocardial necrosis caused by an unstable ischemic state. The
disorder is diagnosed and assessed based on clinical evaluation,
electrocardiogram (ECG), biochemical testing, invasive and
non-invasive imaging, and pathological evaluation. The usual
triggering event of acute myocardial infarction is the rupture
or erosion of a vulnerable, lipid-laden, atherosclerotic coronary
plaque. This event results in the exposure of circulating blood
to highly thrombogenic core and matrix materials in the plaque
(Badimon et al., 2012). In response to various stimuli, the
normal endothelium endures phenotypic changes and variations,
collectively known as endothelial dysfunction, characterized by
a loss of the majority of the homeostatic mechanisms present
in normal healthy endothelial cells. Usually, this dysfunction is
associated with upregulation of adhesion molecules, enhanced
production of ROS, synthesis of pro-inflammatory factors
and loss of vascular tone (Figure 1) (Sitia et al., 2010).
Recent studies suggest that this dysfunction contributes to the
progression of the atherosclerotic plaque (Zardi and Afeltra,
2010). The pioneer role played by endothelial dysfunction in
vascular pathology is supported by observations that individuals
without any clinical sign of atherosclerosis but with high
cardiovascular risk already present an endothelial dysfunction
indicated by a diminished response to some vasodilators, such
as acetylcholine (Zardi and Afeltra, 2010). These findings
FIGURE 1 | Graphical representation of vascular changes occurring in PH and atherosclerosis. Narrowing of the artery lumen is caused by intimal proliferation (PH)
and by plaque formation (atherosclerosis) and is a result of disease specific EC dysfunction and cellular metabolic switches. EC, endothelial cell; PDK, pyruvate
dehydrogenase kinases; ROS, reactive oxygen species; NO, nitric oxide; PH, in pulmonary hypertension.
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suggest that endothelial dysfunction may precede and constitute
a link between different vascular diseases and represents
a good predictor of future cardiovascular events, including
atherosclerotic diseases and AMI (Sitia et al., 2010). Endothelial
dysfunction is considered a systemic vascular process that not
only leads to plaque formation, but also determines the clinical
course of atherosclerosis progression and associated coronary
syndromes. Because several metabolic pathway abnormalities,
such as the deregulation of the nitric oxide production and
the excessive generation of ROS (Table 1), are associated with
atherosclerosis, the identification of key metabolic mechanisms
underlying such alterations should provide fresh opportunities
for the development of new strategies for the treatment
of endothelial cell dysfunction in atherosclerosis and related
vascular pathologies (Bierhansl et al., 2017).
Metabolic Alterations and Requirements in
Acute Myocardial Infarction
Atherosclerosis is characterized by the presence of an uncoupled
and reduced eNOS, causing an imbalance between the
production of NO, an anti-atherogenicmolecule, and superoxide,
a pro-atherogenic factor, thereby losing the atheroprotective
function of eNOS (Eelen et al., 2015). As such, two general
processes are largely responsible for the angiogenic growth
observed in early atherogenesis: inflammation and oxidative
stress. These metabolic alterations also affect, to a variable degree,
vascular remodeling and coagulation homeostasis (Humbert
et al., 2014). Beyond eNOS, a critical role in atherogenesis is
also played by NADPH oxidase (NOX) enzymes, a large family
of enzymes that are pivotal in the generation of ROS in the
vasculature. NOX-4 is universally expressed in vascular smooth
muscle cells (VSMCs), the primary components of the vascular
wall and crucial determinants of vascular homeostasis and
disease (Lu et al., 2013). Its expression and activation during
the angiogenic process promotes a chain of events leading to
vascular inflammation, cellular dysfunction, and atherosclerosis.
Additional metabolic mechanisms may contribute to
the generation of a pro-inflammatory environment leading
to atherogenesis. For example, the high glycolytic mode
encountered in endothelial dysfunction implies a relative
reduction in available ATP as compared to cells with
OXPHOS-predominant metabolism. This results in diminished
intracellular adenosine levels which drives hydrolysis of S-
adenosylhomocysteine (SAH) to adenosine and L-homocysteine
TABLE 1 | Summary main metabolic perturbations in AMI and PH.
AMI Pulmonary Hypertension
Nitric Oxide ↓ NOa,b ↓ NOd
Proliferation ↓ proliferationc ↑ proliferatione
Metabolism ↓Glycolysisa ↓ OXPHOS ↑ Glycolysisf
Antioxidants and ROS ↑ mROSa,b ↓MnROS (↑O−2 /↓H2O2)
g
aEelen et al., 2015; bFörstermann and Sessa, 2012; cLu et al., 2013; dBudhiraja et al.,
2004; eHumbert et al., 2004; Masri et al., 2007; fXu et al., 2007; Xu and Erzurum, 2011;
Lewis, 2014; Bujak et al., 2016; gArcher et al., 2008.
(Hcy). Reduced SAH levels foster histone H3 lysine 4
hypomethylation and overexpression of a pro-inflammatory
gene repertoire (Xu et al., 2017). A recent study (Ward-Caviness
et al., 2017) identified three metabolic biomarkers, arginine
and two lysophosphatidylcholines (LPC 17:0 and LPC 18:2)
associated with incident myocardial infarction (MI). This study
also focus on the association between these metabolites and
the high-sensitivity C reactive protein (hsCRP), which is a
measure for inflammation (Kaptoge et al., 2012). The three
biomarkers correlated with each other and with the hsCRP
levels, suggesting that inflammation can represent a pathway
through which these biomarkers are associated with MI (Cheng
et al., 2012). As a consequence of these processes, increased
rates of apoptosis are evident in more advanced atherosclerotic
plaques. This is a key point in the progression of atherosclerosis
and consists of a programmed cell death, morphologically
expressed as cellular contraction, condensation of chromatin,
and disruption of the cellular membrane. All cells existing in the
atherosclerotic plaque, including lymphocytes, endothelial cells,
smooth muscle cells, and macrophages, can undergo cellular
apoptosis (Schrijvers et al., 2005).
Future Treatment Options in AMI
Currently, the use of beta blockers and angiotensin-converting
enzyme (ACE)-inhibitors are under study for the treatment
of AMI, as well as improvements in antithrombotic therapies.
Despite the advances of the last decades, a lot is unknown about
the biological processes involved in cardiac development and
repair for this reason there is a strong need to find new successful
therapeutic targets to struggle this disease (Ibanez et al., 2018).
Metabolomic approaches can identify potential biomarkers
with predictive value for CVD (Hoefer et al., 2015) and correlate
metabolic profiles with risk of death or incident MI (Shah et al.,
2010). Several studies focus on the limitations of current vascular
biomarkers, like hsCRPs (high sensitive C reactive proteins) and
encourage the discovery and validation of novel biomarkers using
emerging omics technologies. HDL cholesterol is considered
strictly linked to cardiovascular diseases: low HDL cholesterol
is associated to a very high cardiovascular risk while high
HDL cholesterol seems to be linked to cardiovascular protection
(Rohatgi et al., 2014). It has been described, that the key role of
HDL is to promote the eﬄux of the cholesterol and to invert
its transport from the periphery to the liver, which seems to be
correlated to a low incidence of cardiovascular events, suggesting
the potential use of HDL as a new biomarker for coronary heart
disease (Hoefer et al., 2015).
The detection of plasma-derived markers which include
microparticles (MPs), microvesicles and exosomes in human
plasma, has triggered increasing interest for their potential as
biomarkers. In particular, levels of MPs expressing CD31 or
CD144 seem inversely correlated to the endothelium associated
vasodilation highlighting that MPs’ levels might be good
indicators of vascular lesions and acute endothelial dysfunction
(Lacroix et al., 2010). Moreover, the complex composition of
these microparticles which comprise proteins, lipids, and nucleic
acids represent an interesting onset for omics based analysis
(Kanhai et al., 2013). Recent studies have also unveiled that
Frontiers in Molecular Biosciences | www.frontiersin.org 7 January 2019 | Volume 5 | Article 120
Smolders et al. Metabolic Alterations and Endothelial Dysfunctionality
micro-RNAs (miRNAs) not only present relevant intracellular
functions, but also show potential value as cardiovascular disease
biomarkers. miRNAs also circulate within microvesiscles and
may contribute to forecast heart failure, early atherosclerosis
and plaque vulnerability by targeting vascular and cardiac cells
(Matsumoto et al., 2013).
Metabolomic studies using general population-based cohorts
have recently been performed using LC-MS/MS-based lipidomics
and NMR-based approaches to identify species associated with
incident CVD with a potential link to systemic inflammation
and in particular, pro-inflammatory lipid metabolites have
acquired great interest in the cardiovascular disease frame
(Hoefer et al., 2015). Molecular lipid profiling by mass
spectrometry and nuclear magnetic resonance spectroscopy, as
proteomic identification and quantification of small metabolites,
can improve the individual cardiovascular risk prediction
(Stegemann et al., 2014).
The identification of potential metabolic targets for novel
therapeutic approaches for acute myocardial infarction is
therefore an interesting approach that should be investigated in
earnest in the near future.
Endothelial Dysfunction in Pulmonary
Hypertension
The pulmonary vascular barrier consists of three cellular
layers: an external layer, the adventitia containing fibroblasts,
a medial layer mainly consisting of smooth muscle cells
(SMC) lined by an elastic membrane and an internal intima
composed of a single layer of endothelial cells in direct
contact with the blood circulation (Jeffery and Morrell, 2002).
Upon abnormal activation, the normally quiescent endothelium
loses its homeostatic function, leading to a disorganization
of the three-layer structure of the vascular wall as a key
element in the development of pathological lesions (Budhiraja
et al., 2004; Xu and Erzurum, 2011). Several endothelium
activation stimuli such as ROS, shear stress and inflammation
are known to stimulate the endothelium, causing changes in
its proliferation status and production of vasoactive mediators
and growth factors. In PH, it has been shown that there is
an imbalance between vasodilators, such as nitric oxide (NO)
and prostacyclin (PG), and vasoconstrictors, such as endothelin-
1 (ET-1) and thromboxane, resulting in the disruption of
basal pulmonary vascular tone, vascular injury repair and
growth (Budhiraja et al., 2004). In addition to changes in
vasoactive mediators, it is hypothesized that initial endothelial
damage induces a widespread endothelial cell death cascade
leading to an apoptosis-resistant population, from which rapidly
proliferating cells regenerate the vascular lining (Figure 1)
(Masri et al., 2007). Additionally, endothelium injury also
causes exposure of the medial and adventitial layer to growth
factors, inducing the proliferation of fibroblasts and smooth
muscle cells (Budhiraja et al., 2004). Furthermore, disease-
related alterations in the function and expression of specific ion
channels in pulmonary artery smooth muscle cells (PASMC)
and endothelial cells contribute to increased vascular tone,
proliferation., and decreased apoptosis in PAH. Well-studied
as important contributors to continuous vasoconstriction and
remodeling of pulmonary arteries are dysfunctional K+ channels
and altered levels of cytosolic Ca2+(Makino et al., 2017).
Regulatory dysfunctions in fibroblasts are an additional factor
leading to impaired vascular function and remodeling. Studies
in PAH have shown a rise in the deposition of extracellular
matrix (ECM) proteins in the adventitia facilitating themigration
of fibroblasts to the medial and endothelium layers (Stenmark
et al., 2006). The overall result is the emergence of an aberrant
apoptosis-resistant, highly proliferative pulmonary vascular
endothelium together with disruptions in both fibroblasts and
PASMC layers.
Previous research has suggested that PAH ECs derived from
obstructive plexiform lesions are likely associated with alterations
of cellular functions involved in apoptotic and proliferative
processes (Humbert et al., 2004). PAH ECs display faster growth
rates as compared to non-diseased pulmonary ECs, as shown
by enhanced cellular survival signals and increased cell division.
This increased ability to maintain cell viability is accompanied
with an upregulation of pro-survival factors and continuous
activation of signal transducers and activators of transcription
(STATs), such as STAT3, with a known involvement in cell growth
regulation (Masri et al., 2007).
In CTEPH, several studies have highlighted the existence
of an altered cellular phenotype in cells derived from large
arteries. Pulmonary arterial ECs (PAECs) derived from CTEPH
patients showed enhanced mitogenic activity in vitro (Quarck
et al., 2012). This was concomitant with the presence of small-
vessel abnormalities such as thickening of the medial layer and
increased proliferative characteristics of cells lining the internal
intimal layer, and formation of obstructive plexiform lesions
comparable with features seen in PAH, which suggests the
possibility that both diseases might develop from a common
endothelial dysfunction that contribute to vascular remodeling
(Piazza and Goldhaber, 2011). A deeper understanding of the
cellular processes behind these endothelial abnormalities might
therefore shed light on the precise mechanisms that underlie the
pathological changes occurring in the vascular wall of PAH and
CTEPH.
Metabolic Alterations and Requirements in
Pulmonary Hypertension
To better understand pulmonary vascular remodeling processes,
we will take a closer look at the metabolic alterations and
requirements of ECs in PH. As described above, endothelial
cells are highly dynamic and rely mostly on glycolysis for their
energy production and, when stimulated, they further boost the
glycolytic rate to support their higher growth rates.
Both in vitro and in vivo studies have described an increase
in glycolytic rate and lactate release in PAECs derived from
PAH patients, as compared to non-diseased PAECs (Xu et al.,
2007; Xu and Erzurum, 2011). These findings suggest that
glucose metabolism is the primary energy source in PAEC.
Additionally, PAHPAEC showed decreased oxygen consumption
and maintained similar ATP levels under normoxia and hypoxia,
compared to control PAECs (Xu et al., 2007). Despite a
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significant scientific effort in the past years, we are still not
able to fully understand regulatory mechanisms that promote
the switch from oxidative glucose metabolism to glycolysis. A
possible explanation is an impaired mitochondrial function,
including pathological activation of pyruvate dehydrogenase
kinase (PDK) activity and MnSOD deficiency (Archer et al.,
2008; Hernandez-saavedra et al., 2017). It has been shown that
pyruvate dehydrogenase kinases (PDK) are highly expressed
in PAH, which may imply a stronger inhibition of PDH
and thus a proneness toward aerobic glycolysis (Cottrill and
Chan, 2013; Ryan and Archer, 2015). Reduced levels of
MnSOD in PAH disturb the cellular redox status leading to an
accumulation of superoxide anion O−2 and a reduced production
of signaling moleculeH2O2 followed by normoxic activation of
the redox-sensitive HIF1α. This pseudohypoxic state, decreased
MnSOD and increased PDK in the presence of normal PO2,
further favors glycolysis and causes a cascade of downstream
pathways promoting proliferation and inhibiting apoptosis
trough increased cytosolic Ca2+ and K+ concentrations,
respectively, both induced by a downregulation of Kv1,5 channel
(Archer et al., 2008).
Recent metabolic studies focus on the less invasive technique,
metabolomics of biofluids in PH. Despite contrasting reports
using this approach regarding PAH (Zhao et al., 2014; Bujak
et al., 2016), it is a promising technique in search of disease
specific biomarkers. Metabolic profiling in PH has complement
findings from in vitro and in vivo studies regarding increased
glycolysis and has additionally found an increase in PPP, decrease
in fatty acid oxidation (FAO) and impaired TCA (Lewis, 2014;
Bujak et al., 2016). All these observations point to similarities
in metabolic profiles between diseased endothelia in PAH
and rapidly growing cells, thus suggesting the existence of a
Warburg effect in PAH PAECs together with the presence of
mitochondrial abnormalities as summarized in Table 1. It will
be interesting to determine whether CTEPH ECs also present
similar pathophysiological metabolic processes.
Future Treatment Options in PAH and CTEPH
The above described metabolic transformations in PAH
ECs (enhanced glycolytic flows and diminished oxidative
metabolism) bear similarities to the metabolic profiles of
hyperproliferative ECs. On that basis, pharmacological blockade
of PFKFB3, which restraints angiogenesis (Schoors et al., 2014),
offers a window of opportunity to rein in the hyperproliferative
state in PAH ECs by reducing their glycolytic rate (Goveia
et al., 2014). In vitro studies indicated that a dose-dependent
inhibition of PFKFB3 by small compounds such as 3PO (3-(3-
pyridinyl)-1-(4-pyridinyl)-2-propen-1-one) successfully reduced
glycolysis partially (35–40%) although sufficiently to impair EC
proliferation (Schoors et al., 2014). The enhanced expression of
the PDK enzymes in PAH and CTEPH ECs offers an additionally
opportunity for new targeted therapies. Preclinical intervention
models of pulmonary hypertension have been studied to evaluate
the efficacy of PDK inhibition in limiting and/or overturning
pulmonary vascular changes (Harvey and Chan, 2017). The
small molecule dichloroacetate (DCA), a pyruvate analog, has
a relatively high specific binding to PDK (McMurtry, 2004).
In rat models of monocrotaline-induced PAH (MCT-PAH),
DCA was shown to prevent and reverse pulmonary vascular
remodeling. Further, DCA induced apoptosis in the MCT-PAH
pulmonary arteries (PAs) and suppressed cell growth rates
measured by bromodeoxyuridine (BrdU) uptake in the medial
layer of remodeled MCT-PAH PAs with little impact on normal
pulmonary vascular cells in rats and humans, making it a
promising small molecule for targeted restoration of normal
metabolic dysfunctions in PAH ECs (Stacpoole et al., 2003;
McMurtry, 2004; Ryan and Archer, 2015). A recently published
work demonstrated in a first-in-human clinical trial that
PDK inhibition has a positive effect on the hemodynamics of
PAH patients, further supporting the potential of DCA as a
pharmacological agent in this disease (Michelakis et al., 2017).
Growing evidence of the existence of metabolic remodeling
beyond the glycolytic pathway leads to a growing list of possible
metabolic targets. One of these targets is themethylation of SOD2
(MnSOD) which suppresses expression of this redox enzyme.
5-AZA (5-aza-2′-deoxycytidine) inhibits methylation of SOD2
followed by restoration of the mitochondrial respiration (Harvey
and Chan, 2017). Nevertheless, future metabolic studies in larger
PAH patients groups and CTEPH patients will be as necessary
as additional steps in unraveling further pathophysiological
mechanisms. However, one needs to bear in mind the challenges
of metabolic therapies linked to interpatient variations and target
selectivity but also due to the complexity of cell metabolism
itself. Together with the search for new pharmacological
interventions, a broad metabolomic screening is indispensable
in the search for biomarkers in PAH and CTEPH that may help
early diagnosis and uncover metabolic-mediated remodeling
in PH.
CONCLUSIONS AND PROSPECTS
There is increasing evidence that endothelial dysfunction
in cardiopulmonary vascular disorders is associated with
disease-specific metabolic alterations in endothelial cells. Such
reorganization of metabolic networks is a double-edged sword as,
on the one hand, it can function as a defense mechanism against
disease-associated external insults, such as changes in glucose or
oxygen availability, while, on the other hand, it can contribute to
the generation of toxic end-products, anomalous accumulation
of metabolic intermediates and alterations in energetic and
redox metabolism that compromise physiological endothelial
functions. This review points out current metabolic changes
that have a great impact on the onset and progression of both
atherosclerosis and PH. Endothelial cells’ ability to easily switch
between glycolysis, OXPHOS, PPP, and FAO makes the cellular
metabolic switch a complex and challenging target in the search
for future pharmacological interventions.
Targeting endothelial cell metabolism is a promising strategy
to restore normal endothelial function and it has been reported
that moderate inhibition of PFKFB3 can block pathological
angiogenesis and normalize EC dysfunction, whereas strong
inhibition can result in vessel disintegration (Conradi et al.,
2017). This strategy could be useful to restore endothelial
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cell function in pulmonary arterial hypertension (PAH), and
possible also in CTEPH, both characterized by abnormal growth
and enhanced glycolysis of pulmonary artery endothelial cells
(Caruso et al., 2017). The main metabolic perturbations in
pathological ECs in atherosclerosis, acute myocardial infarction
and PH impact distinct pathways that lead to an imbalance in
NO metabolism and ROS production. These diverse metabolic
alterations in different EC dysfunctional pathologies highlight
the need to apply metabolic network modeling approaches to
identify key players that may be specific of endothelial metabolic
dysfunctions and to rationally design interventions to target
pathological ECmetabolism for therapeutic benefit. Although the
key players in glycolysis and energetic metabolism as well as in
NO and ROS balance have been described, and communalities
among different cell types and tissues have been reported, we still
have only partial knowledge on the weight of each enzyme on the
metabolic network fluxes in different cell types or in pathological
vs. healthy states. Techniques and algorithms developed in the
past few years permute an accurate modeling of metabolic
network fluxes that, in conjunction with “omics” approaches,
lay the foundations for unbiased and large-scale identification
of targets with the greatest potential for specifically modulating
metabolic pathway flux in disease conditions.
For medium-scale metabolic network models, among the
main approaches used to model metabolic pathways are those
based on the use of stable-isotope tracers (such as 13C labeled
metabolites). Computational tools to reconstruct metabolic flux
maps from the quantification of the incorporation of 13C-atoms
intometabolites have been developed in recent years (e.g., Young,
2014; Antoniewicz, 2015; Foguet et al., 2016).
Models considering the kinetic properties of each enzyme
in the metabolic network, in combination with methodologies
such as Metabolic Control Analysis (MCA), a methodology to
quantitatively evaluate the relative contribution and importance
of each metabolic step in controlling overall metabolic flux
distribution, have also been successfully used to predict putative
drug targets (Hornberg et al., 2007). The control that each
individual enzyme has on the flux through a metabolic pathway
is quantified using MCA methodology in terms of the so-
called “flux control coefficients.” MCA can be used also to
compare metabolic flux distribution in healthy vs. pathological
condition. These comparisons will permit to identify the
steps with the greatest potential for target specific metabolic
adaptations accompanying pathological states and restore the
flux distribution in health condition.
For large-scale models, constraint-based genome-scale
metabolic models (GSMMs) have been developed and used in
the last years to successfully predict putative therapeutic targets
in different types of cancer (Ryu et al., 2015; Nilsson and Nielsen,
2016; Zhang and Hua, 2016; Yilmaz and Walhout, 2017). In
brief, GSMMs mainly use transcriptomics and other “omics”
data to constraint metabolic flux maps as well as flux balance
analysis (FBA) methods to optimize for a cellular objective
function. The main challenge in this approach is to appropriately
define the objective function. To identify drug targets that
impact abnormal endothelial cell growth, the most used objective
function has been the maximization of biomass production.
Using this approach, putative drug targets have been identified
relevant to cancer through a systematic search for essential genes
and combinations of target genes interacting in a synthetic lethal
fashion able to impair biomass production.
As a word of caution, although topology, stoichiometry
and chemical reaction properties are the major constraints
on metabolic network flux, the consequences of inhibiting an
enzyme activity on the overall network flux redistribution will
depend on the relative concentrations of the different enzymes
in the network (Cascante et al., 2002; De Atauri et al., 2011; Kell
and Goodacre, 2014). Relative levels of enzyme concentrations
in human metabolic networks are different not only in different
tissues and in health vs. disease conditions but also between
individuals which can result in different patient responses to
identical metabolic drug interventions. Endothelial cell metabolic
alterations associated with cardiopulmonary vascular disorders
have been mainly studied using immortalized cell models and
there is a shortage of studies characterizing ECs from patient
tissues, a necessary next step forward in the field.
The therapeutic possibilities of targeting EC metabolism
to improve cardiopulmonary vascular dysfunction are still
understudied. However, we predict that deeper characterization
of metabolic reprogramming in patient-derived cells and
systemic approaches that integrate “omics” data into
comprehensive metabolic network flux models will soon permit
to identify putative key players in endothelial dysfunction
associated with cardiovascular disorders and to design
personalized multi-hit interventions at the metabolic level
to restore physiological endothelial functions.
Finally, growing interest has focused on the modulation of gut
microbiota as a therapeutic strategy in cardiovascular diseases.
Microbiota stability is essential in human physiology, as it is
involved in the regulation of many host functions such as blood
pressure control, glucose tolerance, insulin sensitivity, and body
weight control among others. Since hypertension and metabolic
disturbances are well-known risk factors of CVD development,
it is inevitable to touch in this review the possible role of
gut microbiota and its impact on the cardiovascular system
(Serino et al., 2014; Tang et al., 2017). In humans, the bacterial
proportion of the gut microbiota consists of mainly Firmicutes
and Bacteroidetes phyla and its ratio is an important indicator
of microbiota stability (Tang et al., 2017). Since gut microbes
primarily use ingested nutrients as fuel, it is not surprising that
changes in dietary patterns alters the gut composition and its
functions (Gentile and Weir, 2018). One way of interaction
between the gut microbiota and the host is through production
of metabolites that are biologically active or further metabolized
by the host (Tang et al., 2017). A meaningful example is
trimethylamine (TMA), a metabolite produced by Firmicutes
phyla that promotes foam cell formation through its hepatic
oxidized form TMA-N-oxide (TMAO) (Serino et al., 2014).
Increased levels of this atherogenic microbial metabolite have
been associated with increased risks of cardiovascular events
(Serino et al., 2014; Tang et al., 2017). Individual differences in the
composition of the gut bacteria, combined to the plasticity of the
microbiota, indicate that a gut microbiota-targeted strategy could
be a promising approach for the prevention and the treatment of
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several metabolic diseases. Despite, to date, little evidence have
provided direct evidence of mechanistic or causal roles of gut
microbiota in human cardiovascular disease suggesting that the
relationship between human and gut microbiota must be further
investigated (Griffin et al., 2017; Gentile and Weir, 2018).
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